The vaccine containing recombinant pertussis toxin induces early and long-lasting protection.
Most acellular pertussis vaccines contain a form of pertussis toxin (PT) detoxified by chemical treatment. The Chiron-Vaccines product is unique because it contains a genetically detoxified pertussis toxin. This molecule showed absolute safety, an antigenic profile similar to wild-type PT, and an immunogenicity that is superior to all chemically detoxified PTs. In the efficacy trial, the vaccine containing the genetically detoxified PT demonstrated early and long-lasting protection.
Rappuoli
R
R
Chiron-Vaccines, Via Fiorentina 1, Siena, 53100, Italy.
D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007223:Infant; D037342:Pertussis Toxin; D010567:Pertussis Vaccine; D011994:Recombinant Proteins; D013997:Time Factors; D010566:Virulence Factors, Bordetella / Q000235:genetics
D010567:Pertussis Vaccine; D011994:Recombinant Proteins; D010566:Virulence Factors, Bordetella; D037342:Pertussis Toxin